These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26566033)

  • 1. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study.
    Fabrizi F; Tarantino A; Castelnovo C; Martin P; Messa P
    Kidney Blood Press Res; 2015; 40(6):584-92. PubMed ID: 26566033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population.
    Fabrizi F; Cerutti R; Nardelli L; Tripodi F; Messa P
    Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):49-56. PubMed ID: 31327620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvanted recombinant HBV vaccine (HBV-AS04) is effective over extended follow-up in dialysis population. An open-label non randomized trial.
    Fabrizi F; Cerutti R; Garcia-Agudo R; Bellincioni C; Porata G; Frontini G; Aoufi-Rabih S; Messa P
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):905-912. PubMed ID: 32144074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.
    Surquin M; Tielemans C; Nortier J; Jadoul M; Peeters P; Ryba M; Roznovsky L; Domán J; Barthelemy X; Crasta PD; Messier M; Houard S
    Hum Vaccin; 2011 Sep; 7(9):913-8. PubMed ID: 21892006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients.
    Kong NC; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; Calbo-Torrecillas F; López de Novales E; Srinivasa K; Stoffel M; Hoet B
    Kidney Int; 2008 Apr; 73(7):856-62. PubMed ID: 18160963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
    Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
    Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
    Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population.
    Fabrizi F; Martin P; Messa P
    Int J Artif Organs; 2015 Dec; 38(12):625-31. PubMed ID: 26821784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine.
    Surquin M; Tielemans CL; Kulcsár I; Ryba M; Vörös P; Mat O; Treille S; Dhaene M; Stolear JC; Kuriyakose SO; Leyssen MX; Houard SA
    Kidney Int; 2010 Feb; 77(3):247-55. PubMed ID: 19940840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.
    Leroux-Roels G; Haelterman E; Maes C; Levy J; De Boever F; Licini L; David MP; Dobbelaere K; Descamps D
    Clin Vaccine Immunol; 2011 Sep; 18(9):1510-8. PubMed ID: 21734063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials.
    Tielemans CL; Vlasak J; Kosa D; Billiouw JM; Verpooten GA; Mezei I; Ryba M; Peeters PC; Mat O; Jadoul MY; Polakovic V; Dhaene M; Treille S; Kuriyakose SO; Leyssen M; Houard SA; Surquin M
    Vaccine; 2011 Feb; 29(6):1159-66. PubMed ID: 21167859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
    Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
    Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
    Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
    Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
    Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
    J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transiently positive hepatitis B surface antigen after vaccination with the new hepatitis B vaccine HBV-AS04.
    Vanacker A; Vandewiele I; Verbanck J; Schepkens H; De Schoenmakere G; De Laere E; Maes B
    Am J Kidney Dis; 2008 Nov; 52(5):1028-9. PubMed ID: 18971027
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients.
    Tung J; Carlisle E; Smieja M; Kim PT; Lee CH
    Am J Kidney Dis; 2010 Oct; 56(4):713-9. PubMed ID: 20630640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.
    Boland G; Beran J; Lievens M; Sasadeusz J; Dentico P; Nothdurft H; Zuckerman JN; Genton B; Steffen R; Loutan L; Van Hattum J; Stoffel M
    Vaccine; 2004 Dec; 23(3):316-20. PubMed ID: 15530674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
    Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
    Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.